Comparison of the Effects of TFPB and Anterior QLB on Postoperative Analgesia in Cesarean Section Surgery

Sponsor
Ondokuz Mayıs University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05408403
Collaborator
(none)
50
1
2
3
16.5

Study Details

Study Description

Brief Summary

This study evaluates the postoperative analgesic effects of transversalis fascia plane block and anterior quadratus lumborum block in patients having cesarean section under general anesthesia. General anesthesia will be performed to all patients for the surgery.

Condition or Disease Intervention/Treatment Phase
  • Other: Regional anesthesia TFPB
  • Other: Regional anesthesia QLB
N/A

Detailed Description

In this study, patients are divided into two groups. After the general anesthesia is performed and cesarean section surgery is over; TFPB block will be performed to patients in Group A ; while anterior QLB block will be performed to patients in Group B. In addition, patient controlled analgesia (PCA) will be used in the first 24 hours postoperatively. Group A - Patients in group A will have TFPB block after the surgery. In addition, patient controlled analgesia (PCA) will be used in the first 24 hours postoperatively. Group B - Patients in group B will have anterior QLB block after the surgery. In addition, patient controlled analgesia (PCA) will be used in the first 24 hours postoperatively.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomization of the study will be done by a doctor who will not participate in patient follow-up with closed envelopes using computer-generated randomization codes.Randomization of the study will be done by a doctor who will not participate in patient follow-up with closed envelopes using computer-generated randomization codes.
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
The anesthesia doctor who will perform the interfascial plane block (TFPB, anterior QLB) will be informed with a sealed envelope by an independent assistant outside the study, and the patient will not know which block is performed.
Primary Purpose:
Supportive Care
Official Title:
Comparison of the Effects of Transversalis Fascia Plane Block and Anterior QLB ( TFPB and Anterior QLB ) on Postoperative Analgesia in Cesarean Section Surgery
Anticipated Study Start Date :
Jun 18, 2022
Anticipated Primary Completion Date :
Aug 18, 2022
Anticipated Study Completion Date :
Sep 18, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Transversalis Fascia Plane Block

Transversalis Fascia Plane Block (TFPB) will be performed the patients in Group A after the cesarean section surgery. Patient controlled analgesia device (PCA) is used for all the patients in the first 24 hours postoperatively

Other: Regional anesthesia TFPB
Transversalis Fascia Plane Block will be performed with 25 mL of 0.25% bupivacaine,after the end of cesarean surgery before extubation.
Other Names:
  • Transversalis Fascia Plane Block
  • Active Comparator: Quadratus Lumborum Block

    Anterior Quadratus Lumborum Block ( Anterior QLB) will be performed the patients in Group B after the cesarean section surgery. Patient controlled analgesia device (PCA) is used for all the patients in the first 24 hours postoperatively

    Other: Regional anesthesia QLB
    Anterior Quadratus Lumborum Block will be performed with 25 mL of 0.25% bupivacaine, after the end of cesarean surgery before extubation.
    Other Names:
  • Anterior Quadratus Lumborum Block
  • Outcome Measures

    Primary Outcome Measures

    1. Opioid consumption in the first 24 hours after surgery [Postoperative Day 1]

      Morphine consumption in the first 24 hours will be counted by IV patient controlled analgesia device (PCA). Patients will be able to request opioids via PCA device when the nrs score is above 4.

    Secondary Outcome Measures

    1. Post-operative acute pain [Postoperative Day 1]

      Pain status will be evaluated based on numeric rating scale (NRS) scores at rest and after movement. Pain status will be evaluated at 1, 3, 6, 9, 12, 18, 24. hours after surgery. Each NRS is scores 0-10. (0=no pain ; 10=worst pain imaginable)

    2. The time of first opioid requirement [Postoperative Day 1]

      The time of first opioid requirement will be recorded during the postoperative first 24 hours

    Other Outcome Measures

    1. The incidences of post-operative nausea and vomiting (PONV) [Postoperative Day 1]

      the presence of nausea and vomiting will be recorded for 24 hours after surgery

    2. The incidence of side effects related to local anesthetics, opioid use and regional anesthesia technic [Postoperative Day 1]

      respiratory depression, local anesthetic (LA) toxicity, hematoma and organ damage.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Being pregnant for at least 37 weeks

    • Planning an elective cesarean operation

    • Being between the ages of 18-45

    Exclusion Criteria:
    • American Society of Anesthesiologists (ASA) 3-4 patients with comorbidities (Serious renal, cardiac, hepatic disease)

    • Being operated with spinal anesthesia

    • Obesity (> 100 kg, BMI> 35 kg / m2)

    • Contraindication of regional anesthesia (coagulopathy, abnormal international normalized ratio (INR), thrombocytopenia, infection at the injection site)

    • Hypersensitivity to local anesthetics or a history of allergy

    • Patients with a history of opioid use longer than four weeks

    • Patients with psychiatric disorders

    • Patients with anatomic deformity

    • Patients who do not want to participate

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ondokuz Mayıs University Faculty of Medicine Samsun Turkey 55200

    Sponsors and Collaborators

    • Ondokuz Mayıs University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    SEZGİN BİLGİN, Medical Doctor, Ondokuz Mayıs University
    ClinicalTrials.gov Identifier:
    NCT05408403
    Other Study ID Numbers:
    • TFPB-QLB3
    First Posted:
    Jun 7, 2022
    Last Update Posted:
    Jun 13, 2022
    Last Verified:
    Jun 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by SEZGİN BİLGİN, Medical Doctor, Ondokuz Mayıs University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 13, 2022